Poway, California (PRWEB) April 24, 2014
Vet-Stem, Inc., announced that a non-exclusive European license agreement has been signed with a global human stem cell company. This license provides access to the newly issued Vet-Stem patent for the extraction methods and the use of adipose-derived stem cells in prevention and treatment of diseases in the human. Vet-Stem retains all rights outside of the human field.
As the first and largest company in the world to offer fat-derived stem cell services for veterinary use, Vet-Stem has rapidly developed the market, treating over 10,000 horses and dogs. In its veterinary development, Vet-Stem has collaborated closely with leading companies and academic institutions worldwide involved in bringing this technology to the human markets. Vet-Stem’s patent covers both veterinary and human applications and it seeks to license the human applications to additional interested companies.
“Intellectual property rights can be confusing in a rapidly developing market with evolving technology,” said Bob Harman, DVM, MPVM, CEO of Vet-Stem. “We have in-licensed the strongest patents in the world to protect the market that we are creating in regenerative veterinary medicine and to ensure that the value of the company is optimized. Now with this additional patent issued directly to Vet-Stem, we can collaborate directly with companies developing human therapeutics in the cell therapy space.”
Vet-Stem currently offers stem cell services to veterinarians for treatment of lameness in horses and for arthritis in dogs and cats. New uses of regenerative cells are in development for diseases in dogs, cats and horses that often times have few other treatment options.
About Vet-Stem, Inc.
Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.’s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.